Review Article
Medical Therapy of Acromegaly
Table 3
Comparison of primary versus secondary medical therapy (mTx).
| | | Medication | Dose | Remission (% of pats) | Criteria for remission | Author | GH | IGF-1 | GH | IGF-1 |
| Prim. mTx | 26 | Octr. s.c. | 777 g/d (mean) | 43 | 68 | <2 g/L | Normal** |
Newman et al. 1998 [135] | Sec. mTx | 81 | | 635 g/d (mean) | 22 | 62 | | | | | | | | | | |
| Prim. mTx | 23 | Lanr. SR | 30 mg/10–14 d | 64 | 51 | basal GH < 7.5 U/L | Normal* |
Baldelli et al. 2000 [136] | Sec. mTx | 71 | | | 78 | 70 | | | | | | | | | | |
| Prim. mTx | 15 | Octr. LAR | 10–40 mg/mo | 73 | 53 | <2.5 g/L or <1 g/L (oGTT) | Normal* |
Colao et al. 2001 [119] | Sec. mTx | 21 | | | 76 | 71 | | | | | | | | | | |
| Prim. mTx | 10 | Octr. LAR or Lanr. SR | 20 mg/6 w–30 mg/4 w | 50 | 60 | <2 g/L | Normal* |
Ayuk et al. 2002 [134] | Sec. + prim. mTx | 22 | | 30 mg/2 w–30 mg/10 d | 36 | 62 | | |
|
|
IGF-1 concentration, age adjusted; IGF-1 concentration, not age adjusted.
|